Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus gefitinib vs gefitinib in EGFR-mutant non-squamous NSCLC (China)
CTR20132620Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pemetrexed, gefitinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Eli Lilly and Company. Started May 2014; status: active.
02
Drugs
pemetrexedgefitinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20132620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132620.